Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Esteva on the Clinical Implications of Genomic Testing for Breast Cancer

September 1st 2017

Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses the clinical implications of genomic testing in breast cancer.

Baylor Team Helps Establish Scalp-Cooling Benefits for Breast Cancer Patients

August 31st 2017

Supported by research, there have been recent developments in using scalp cooling to combat chemotherapy-induced alopecia for patients with breast cancer.

Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer

August 31st 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

BRCA1/2 Mutation Genetic Status Linked With Platinum Resistance in Breast and Ovarian Cancers

August 31st 2017

Katherine Nathanson, MD, discusses how the genetics of BRCA1/2-associated tumors impacts tumor development in breast and ovarian cancer and response to treatment.

FDA Delays Decision on Trastuzumab Biosimilar MYL-1401O

August 30th 2017

The FDA has extended its decision deadline by 3 months on a biologics license application for MYL-1401O, a trastuzumab biosimilar co-developed by Mylan and Biocon. A final decision is expected on or before December 3, 2017.

FDA Grants DS-8201 Breakthrough Designation for HER2+ Breast Cancer

August 30th 2017

The investigational HER2-targeting antibody-drug conjugate DS-8201 has received an FDA breakthrough therapy designation for the treatment of patients with HER2-positive, locally advanced, or metastatic breast cancer.

Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast Cancer

August 29th 2017

Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

FDA Approves Frontline Fulvestrant for HR-Positive/HER2-Negative Breast Cancer

August 28th 2017

The FDA has approved fulvestrant for use in hormone receptor-positive, HER2-negative locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.

Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

August 25th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Frontline Ribociclib Approved in Europe for HR+/HER2- Breast Cancer

August 24th 2017

The European Commission has approved the CDK 4/6 inhibitor ribociclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative locally advanced or metastatic breast cancer.

Esteva Explains State of Genomic Testing in Breast Cancer

August 23rd 2017

Francisco J. Esteva, MD, PhD, discusses the clinical implications of genomic testing for patients with metastatic breast cancer.

Gradishar Sheds Light on Treatment Trends in Breast Cancer

August 22nd 2017

William J. Gradishar, MD, discusses the latest developments in the HER2-positive setting, as well as biomarker development and the potential for immunotherapy in breast cancer.

Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer

August 18th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

Expert Discusses De-Escalation Difficulties, Other Topics in TNBC

August 13th 2017

Lisa Carey, MD, discusses the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.

Lead Researcher Discusses Latest Pertuzumab Data in HER2+ Breast Cancer

August 12th 2017

Gunter von Minckwitz, MD, PhD, discusses the APHINITY results and their implication for the use of pertuzumab in patients with HER2-positive breast cancer.

Neoadjuvant T-DM1 Improves pCR in HER2+/HR+ Early Breast Cancer

August 11th 2017

Twelve weeks of neoadjuvant T-DM1 with or without endocrine therapy induced superior pathologic complete response compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer

August 11th 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Treatment Considerations in Older Patients With Breast Cancer

August 10th 2017

Arti Hurria, MD, discusses the unique challenges with treating elderly patients with breast cancer and the exciting opportunities she envisions for advancing care in this setting.

Dr. Kuerer on Margins of DCIS

August 10th 2017

Henry M. Kuerer, MD, PhD, professor of surgery, The University of Texas MD Anderson Cancer Center, discusses margins of ductal carcinoma in situ (DCIS).

Pegram Discusses Latest Developments in HER2+ Breast Cancer

August 9th 2017

Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.